Urology · Dover, DE
NPI
1245226828
Since 2005
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
200 Banning St, Suite 250
Dover, DE, 19904
Phone (302) 736-1320
Groups this clinician bills Medicare through
Medicare paid, 2024
$703K
22,282 services
Medicare patients, 2024
1,832
Average age 75
Drug cost, 2024
$2.3M
5,912 prescriptions
Company payments, 2025
$453
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher J Vallorosi was code J9030 (bcg live intravesical instillation, 1 mg), 2,301 times for 21 patients. In total Christopher J Vallorosi billed 22,282 services in 109 codes, and Medicare paid $703K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-09-05.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,301 | 21 | $2.20 | $5,051 |
| J0897 Injection, denosumab, 1 mg | Office | 2,040 | 12 | $21.02 | $43K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,537 | 1,199 | $13.27 | $20K |
| 99214 Office E&M - Established | Office | 1,497 | 1,108 | $93.41 | $140K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,337 | 288 | $52.84 | $71K |
| 81003 Clinical Chemistry | Office | 1,200 | 1,016 | $2.18 | $2,622 |
| 84311 Immunoassay | Office | 1,143 | 544 | $7.93 | $9,062 |
| 87798 Infectious Agent Detection by DNA/RNA | Office | 1,080 | 75 | $34.39 | $37K |
| 82570 Clinical Chemistry | Office | 579 | 549 | $5.07 | $2,937 |
| 82945 Clinical Chemistry | Office | 575 | 545 | $3.84 | $2,211 |
| 82247 Clinical Chemistry | Office | 574 | 544 | $4.91 | $2,820 |
| 83986 Clinical Chemistry | Office | 574 | 544 | $3.50 | $2,012 |
| 83069 Blood Count | Office | 574 | 544 | $3.86 | $2,218 |
| 82010 Clinical Chemistry | Office | 574 | 544 | $8.00 | $4,591 |
| 84156 Clinical Chemistry | Office | 569 | 539 | $3.59 | $2,045 |
By year: 2022 $524K for 12,062 services; 2023 $559K for 13,529 services; 2024 $703K for 22,282 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,200 | 1,016 | $2.18 | $2,622 |
| 84311 Immunoassay | 1,143 | 544 | $7.93 | $9,062 |
| 87798 Infectious Agent Detection by DNA/RNA | 1,080 | 75 | $34.39 | $37K |
| 82570 Clinical Chemistry | 579 | 549 | $5.07 | $2,937 |
| 82945 Clinical Chemistry | 575 | 545 | $3.84 | $2,211 |
| 83986 Clinical Chemistry | 574 | 544 | $3.50 | $2,012 |
| 82247 Clinical Chemistry | 574 | 544 | $4.91 | $2,820 |
| 83069 Blood Count | 574 | 544 | $3.86 | $2,218 |
| 82010 Clinical Chemistry | 574 | 544 | $8.00 | $4,591 |
| 84156 Clinical Chemistry | 569 | 539 | $3.59 | $2,045 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher J Vallorosi prescribed most often to Medicare patients was Finasteride, with 1,518 prescriptions and refills. In total Christopher J Vallorosi wrote 5,912 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Finasteride Generic | 1,518 | 4,428 | 455 | $30K |
| Tamsulosin Hcl Generic | 1,424 | 4,054 | 433 | $26K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 556 | 1,558 | 196 | $19K |
| Myrbetriq Mirabegron | 368 | 880 | 106 | $378K |
| Gemtesa Vibegron | 206 | 500 | 60 | $229K |
| Dutasteride Generic | 191 | 546 | 55 | $9,434 |
| Fesoterodine Fumarate Er Fesoterodine Fumarate | 176 | 470 | 56 | $29K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 174 | 518 | 53 | $5,994 |
| Levofloxacin Generic | 174 | 174 | 148 | $437 |
| Solifenacin Succinate Generic | 132 | 367 | 54 | $7,418 |
| Silodosin Generic | 121 | 354 | 39 | $17K |
| Orgovyx Relugolix | 98 | 98 | 12 | $270K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 69 | 69 | 56 | $882 |
| Testosterone Generic | 53 | 104 | 19 | $13K |
| Tolterodine Tartrate Er Tolterodine Tartrate | 43 | 129 | 14 | $5,128 |
Brand drugs: 818 claims; generic drugs: 5,094 claims; opioid claims: 31.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher J Vallorosi $453 ($453 in general payments such as food, travel and fees) from 13 companies. The largest payer was Sumitomo Pharma America, Inc. with $113.
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. 4506.T | 5 | $113 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $44.8 |
| Astellas Pharma US Inc 4503.T | 2 | $37.46 |
| Bioprotect Medical, Inc. | 2 | $37.45 |
| Procept Biorobotics Corporation PRCT | 1 | $33 |
| Merck Sharp & Dohme LLC MRK | 1 | $30.25 |
| Immunitybio, Inc. IBRX | 1 | $27.73 |
| Urogen Pharma, Inc. URGN | 1 | $25.53 |
| Abbvie Inc. ABBV | 1 | $25.07 |
| Olympus America Inc. | 1 | $24.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.